News

News
Partner news

Provention Bio Announces Closing of Upsized Initial Public Offering

Read full story
Partner news

Asceneuron's Tau Modifier ASN120290 Receives Orphan Drug Designation for Progressive Supranuclear Palsy From the FDA

Read full story
JNJ Press releases

EUSA PHARMA ANNOUNCES ACQUISITION OF GLOBAL RIGHTS TO SYLVANT® (SILTUXIMAB) FROM JANSSEN SCIENCES IRELAND UC FOR $115 MILLION

Read full story
Partner news

Cue Health Completes $45MM Series B Financing

Read full story
JNJ Press releases

Johnson & Johnson Innovation Announces Memorandum of Understanding with Kyoto University to Collaborate in Identifying and Accelerating the Development of Innovative Healthcare Solutions

Read full story